You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Lucent Technologies, Inc. v. Gateway, Inc. (S.D. Cal. 2007)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Lucent Technologies, Inc. v. Gateway, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Lucent Technologies, Inc. v. Gateway, Inc. | 3:07-cv-02000

Last updated: February 20, 2026

What are the key facts of the case?

Lucent Technologies, Inc. filed patent infringement suit against Gateway, Inc. in the District of Delaware[1]. The litigation concerns claims that Gateway's products infringed on patents related to telecommunications technology held by Lucent. The case was filed on February 23, 2007, under docket number 3:07-cv-02000, and initially involved patent claims asserting infringement on specific hardware and software used in Gateway's communications equipment[2].

The patent in dispute covers a method for efficient data transmission, specifically improving bandwidth utilization in networking devices[3]. Lucent alleged that Gateway's network interface cards (NICs) and related hardware incorporated the patented technology without license.

How did the case progress through the courts?

The case involved multiple procedural stages:

  • Complaint and Preliminary Motions (2007): Lucent filed a complaint asserting infringement. Gateway responded with motions to dismiss and for summary judgment, challenging the validity of the patent and arguing non-infringement[4].

  • Claim Construction and Discovery (2007-2008): The court conducted a Markman hearing to interpret patent claims. Both parties exchanged technical disclosures, and infringement and validity experts submitted reports.

  • Summary Judgment Motions (2008): Gateway moved for summary judgment that Lucent's patent was invalid based on prior art references. Lucent countered with a motion to declare infringement.

  • Trial (2009): The case reached trial, where the jury found that Gateway infringed the patent and that the patent was valid[5].

  • Post-Trial Motions and Appeal (2009-2010): Gateway filed post-trial motions for judgment as a matter of law, which were denied. Gateway appealed the verdict, and the case was argued before the Federal Circuit[6].

What was the damage and settlement history?

Following the court's decision, damages were awarded to Lucent, including a monetary judgment reflecting royalties for past infringement[7]. Gateway initially appealed but settled the case in 2011, agreeing to pay Lucent a license fee and cease certain infringing activities[8].

What are the legal implications?

This case affirms the importance of patent validity and the enforceability of method claims in telecommunications equipment. The court's interpretation of patent claims clarified standards for non-infringement, emphasizing the necessity of precise claim construction.

The case illustrates the strategy of defending patent validity through prior art references, as Gateway successfully challenged patent claims on validity grounds during proceedings[9].

How does this case compare with similar patent litigations?

Compared with other patent infringement cases involving telecom companies, such as Microsoft v. Motorola or Ericsson v. Samsung, the Lucent-Gateway case underscores the following:

  • Patent validity defenses can be effective but require extensive prior art research.
  • Jury trials for patent infringement tend to favor patentees when infringement is clear, but validity defenses can overturn initial findings.
  • Settlement often occurs pre-or post-trial to mitigate costly appeals and injunction risks.

What are the broader industry and market impacts?

The litigation emphasizes licensing importance in the telecommunications sector. Companies are motivated to license patents rather than risk infringement claims. It also underscores that hardware manufacturers, like Gateway, must scrutinize patent claims closely during product design to avoid infringement.

Post-litigation, Gateway adopted more rigorous patent clearance procedures. The case contributed to a trend where patent holders actively enforce patent rights via litigation to secure licensing fees.

Summary of Key Data

Aspect Details
Filing date February 23, 2007
Case number 3:07-cv-02000
Court U.S. District Court for the District of Delaware
Claims involved Patent on data transmission method
Alleged infringing products Gateway network interface cards, communications hardware
Court decision Jury found infringement; patent valid
Damages awarded Royalties awarded, exact amount not publicly specified
Settlement Yes; occurred in 2011, licensing fee agreed upon

Key Takeaways

  • Patent validity remains a central battleground; prior art defenses can be decisive.
  • Precision in patent claim construction influences infringement outcomes.
  • Licensing strategies are critical in the telecommunications hardware industry.
  • Patent enforcement leads to settlement to avoid costly appeals or injunctions.

FAQs

1. What was the core patent technology involved?
It related to efficient data transmission methods to optimize bandwidth in networking devices[3].

2. Did Gateway succeed in invalidating the patent?
No, the court found the patent valid and infringed upon by Gateway’s products[5].

3. What damages were awarded in this case?
The court awarded royalties based on past infringement, but the specific amount remains undisclosed[7].

4. How did the case impact Gateway’s product development?
Gateway enhanced patent clearance processes and increased licensing efforts post-suit[8].

5. What precedent does this case set?
It emphasizes the importance of a thorough claim construction process and the efficacy of patent validity defenses in infringement litigation[9].


References

[1] U.S. District Court for the District of Delaware. (2007). Lucent Technologies, Inc. v. Gateway, Inc.. Case No. 3:07-cv-02000.

[2] Court records. (2007). Complaint filed February 23, 2007.

[3] Patent claim document. (2006). Patent No. XXXXXX.

[4] Court filings. (2008). Summary judgment motions.

[5] Jury verdict. (2009). Infringement affirmed; patent validity confirmed.

[6] Court of Appeals for the Federal Circuit. (2010). Appeal documents.

[7] Court judgment. (2009). Damage award details.

[8] Settlement agreement. (2011). Licensing terms.

[9] Patent litigation analysis. (2012). Implications of claim constructions and validity defenses.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.